Evidence map›Paper›PMID 37401970›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

PDGFβ receptor-targeted delivery of truncated transforming growth factor β receptor type II for improving the in vitro and in vivo anti-renal fibrosis activity via strong inactivation of TGF-β1/Smad signaling pathway.

Bing Wang, Xiaohua Wang, Yixin Dong, Xiaohui Liu, Liming Xu, Yong Liu, Yan Wu, Chuntao Wang, Haifeng Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Bing Wang *Heilongjiang Province Key Laboratory for Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Xiaohua Wang *Heilongjiang Province Key Laboratory for Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Yixin DongHeilongjiang Province Key Laboratory for Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Xiaohui LiuHeilongjiang Province Key Laboratory for Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Liming XuHeilongjiang Province Key Laboratory for Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Yong LiuMedical Research Center, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Yan WuHeilongjiang Province Key Laboratory for Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Chuntao WangDepartment of Cell Biology, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China. wangchuntao@mdjmu.edu.cn.
Haifeng LiuHeilongjiang Province Key Laboratory for Anti-Fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China. fenghailiu510@163.com.
Mudanjiang Medical University · CN

Funding

Heilongjiang Provincial Natural Sciences Foundation of China LH2022H098Heilongjiang Provincial Pharmaceutical and Healthcare Project 20220202040669Mudanjiang Applied Technology Research and Development Project HT2022JG128National Natural Sciences Foundation of China 81500471National Natural Sciences Foundation of China 81700544the Doctoral Scientific Research Projects of Mudanjiang Medical University 2021-MYBSKY-061
6 · The paper itself

Abstract

Truncated transforming growth factor β receptor type II (tTβRII), serving as a trap for binding excessive transforming growth factor β1 (TGF-β1) by means of competing with wild-type TβRII, is a promising strategy for the treatment of kidney fibrosis. Platelet-derived growth factor β receptor (PDGFβR) is highly expressed in interstitial myofibroblasts in kidney fibrosis. This study identified the interaction between a novel tTβRII variant Z-tTβRII (PDGFβR-specific affibody Z

Indexed as

Kidney DiseasesTransforming Growth Factor beta1AnimalsFibrosisMiceNIH 3T3 CellsReceptor, Platelet-Derived Growth Factor betaSignal TransductionReceptor, Platelet-Derived Growth Factor betaTransforming Growth Factor beta1Platelet-derived growth factor β receptorRenal fibrosisTransforming growth factor β1Transforming growth factor β receptor type II

Identifiers

PMID37401970
OpenAlexW4383058569

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.